Systematic review: the costs of ulcerative colitis in Western countries

Abstract

Aliment Pharmacol Ther 31, 693–707 Summary Background Early onset and complications such as hospitalization and surgery contribute to the economic burden of ulcerative colitis. Aim To review systematically the literature on costs of ulcerative colitis in Western countries. Methods Studies estimating costs of ulcerative colitis in Western countries were identified using Medline, EMBASE and ISI Web of Science and were rated based on relevance and reliability of estimates. All costs were adjusted to 2008 currency values. A parallel review focused on the impact of disease severity on costs, hospitalizations and surgeries. Results Estimated annual per‐patient direct medical costs of ulcerative colitis ranged from $6217 to $11 477 in the United States and from €8949 to €10 395 in Europe. Hospitalizations accounted for 41–55% of direct medical costs. Indirect costs accounted for approximately one‐third of total costs in the United States and 54–68% in Europe. Total economic burden of ulcerative colitis was estimated at $8.1–14.9 billion annually in the United States and at €12.5–29.1 billion in Europe; total direct costs were $3.4–8.6 billion in the United States and €5.4–12.6 billion in Europe. Direct costs, hospitalizations and surgeries increased with worsening disease severity. Conclusions Ulcerative colitis is a costly disease. Hospitalizations contribute significantly to direct medical costs, and indirect costs are considerable, having previously been substantially underestimated.